Description
Boston Scientific: Inside China’s Explosive MedTech Boom!
Boston Scientific Corporation’s third-quarter performance highlights significant growth, driven chiefly by its Cardiovascular segment, particularly in Electrophysiology (EP) and the WATCHMAN product line. The company’s operational sales ascended by 19%, with organic sales rising by 15%, both exceeding forecasted ranges. This robust performance underscores Boston Scientific’s strategic focus and execution prowess. In terms of geographical performance, the U.S. market showcased a robust 27% growth, driven by widespread gains across Cardiovascular, Endoscopy, and Neuromodulation. Asia-Pacific exhibited a solid 17% operational growth, propelled primarily by Japan and China. Japan’s performance was spurred by products such as the WATCHMAN and EP, while in China, despite challenges from Voluntary Bidding Procurement (VBP) impacting peripheral business sales, Boston Scientific managed mid-teens growth. This growth was supported by launches such as the WATCHMAN FLX Pro in China.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
